Clinical Trials Logo

CAR - T CD19/CD20/CD22/CD30 clinical trials

View clinical trials related to CAR - T CD19/CD20/CD22/CD30.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT03196830 Recruiting - Clinical trials for Refractory Non-Hodgkin Lymphoma

CAR-T for R/R B-NHL

Start date: June 1, 2017
Phase: Phase 2
Study type: Interventional

This study is a single arm study to investigate the efficacy and safety of CAR-T targeted CD19/CD20/CD22/CD30 in relapse and refractory non-Hodgkin lymphoma patients. Ten patients will recruieted, admitted in hospital for 1 month for the CAR-T treatment and follow-up for at least 2 years.